Barbara Imberti1, Manuela Monti, Federica Casiraghi. 1. aCentro Anna Maria Astori, Parco Scientifico Tecnologico Kilometro Rosso, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo bCentro Ricerche di Medicina Rigenerativa-Fondazione IRCCS Policlinico San Matteo, Pavia cCentro Ricerche Trapianti 'Chiara Cucchi de Alessandri e Gilberto Crespi', IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Bergamo, Italy dFondazione IRCCS-Policlinico San Matteo, Pavia, Italy.
Abstract
PURPOSE OF REVIEW: Ongoing research is constantly looking for means to modulate the immune system for long-lasting engraftment of pluripotent stem cells (PSC) during stem cell-based therapies. This study reviews data on in-vitro and in-vivo immunogenicity of embryonic and induced-PSC and describes how their immunological properties can be harnessed for tolerance induction in organ transplantation. RECENT FINDINGS: Although PSC display immunomodulatory properties in vitro, they are capable of eliciting an immune response that leads to cell rejection when transplanted into immune-competent recipients. Nevertheless, long-term acceptance of PSC-derived cells/tissues in an allogeneic environment can be achieved using minimal host conditioning. Protocols for differentiating PSC towards haematopoietic stem cells, thymic epithelial precursors, dendritic cells, regulatory T cells and myeloid-derived suppressor cells are being developed, suggesting the possibility to use PSC-derived immunomodulatory cells to induce tolerance to a solid organ transplant. SUMMARY: PSC and/or their derivatives possess unique immunological properties that allow for acceptance of PSC-derived tissue with minimal host conditioning. Investigators involved either in regenerative or in transplant medicine must join their efforts with the ultimate aim of using PSC as a source of donor-specific cells that would create a protolerogenic environment to achieve tolerance in solid organ transplantation.
PURPOSE OF REVIEW: Ongoing research is constantly looking for means to modulate the immune system for long-lasting engraftment of pluripotent stem cells (PSC) during stem cell-based therapies. This study reviews data on in-vitro and in-vivo immunogenicity of embryonic and induced-PSC and describes how their immunological properties can be harnessed for tolerance induction in organ transplantation. RECENT FINDINGS: Although PSC display immunomodulatory properties in vitro, they are capable of eliciting an immune response that leads to cell rejection when transplanted into immune-competent recipients. Nevertheless, long-term acceptance of PSC-derived cells/tissues in an allogeneic environment can be achieved using minimal host conditioning. Protocols for differentiating PSC towards haematopoietic stem cells, thymic epithelial precursors, dendritic cells, regulatory T cells and myeloid-derived suppressor cells are being developed, suggesting the possibility to use PSC-derived immunomodulatory cells to induce tolerance to a solid organ transplant. SUMMARY: PSC and/or their derivatives possess unique immunological properties that allow for acceptance of PSC-derived tissue with minimal host conditioning. Investigators involved either in regenerative or in transplant medicine must join their efforts with the ultimate aim of using PSC as a source of donor-specific cells that would create a protolerogenic environment to achieve tolerance in solid organ transplantation.
Authors: Ratnesh Singh; Oscar Cuzzani; François Binette; Hal Sternberg; Michael D West; Igor O Nasonkin Journal: Stem Cell Rev Rep Date: 2018-08 Impact factor: 5.739
Authors: Karin Säljö; Angela Barone; Johan Mölne; Lennart Rydberg; Susann Teneberg; Michael E Breimer Journal: Sci Rep Date: 2017-10-12 Impact factor: 4.379